Startup based on Gothenburg research attracts interest in the US
MucoLife Therapeutics, a startup company based on research from the University of Gothenburg, has recently gained attention after presenting its drug candidate at the renowned Science2Startup symposium in Boston. The event brings together investors and experts from some of the world's leading universities and biotech companies.
MucoLife Therapeutics was founded by Professor Gunnar C. Hansson and Associate Professor Thaher Pelaseyed and coworkers, research leaders in mucin biology at the Sahlgrenska Academy, University of Gothenburg. The company is developing an inhalation treatment – MLT-001 – that tackles the problem of mucus plugs in the airways in a new way. These types of blockages are more than just a breathing obstacle – they are serious and contribute both to disease progression and an increased risk of death. They play a key role in the reduced lung function and breathing difficulties seen in conditions like COPD, asthma, and cystic fibrosis.
“MLT-001 is the first treatment that targets the mechanism that makes mucus stiff and difficult to clear. By modulating mucin interactions, we can effectively dissolve mucus plugs,” says Thaher Pelaseyed, CEO of MucoLife Therapeutics.
The treatment has so far been studied in mice and pigs, with results showing that mucus plugs can be reduced by up to 90 percent. Researchers believe the treatment has the potential to make breathing easier, reduce infections, reverse the chronic inflammation, and improve overall quality of life.
“This is a completely new approach that differs from current treatments, which often have limited effects or side effects. We believe that our technology has the potential to truly improve the care of chronic lung diseases,” says Thaher Pelaseyed.
Towards clinical application
MucoLife has received support from both GU Ventures, the commercialization company of the University of Gothenburg, and the American life science accelerator Health Wildcatters. This support has made it possible to take the step from academic research to clinical development.
“Presenting at Science2Startup places us among the world's most promising academic spinouts. It provides important visibility and validation ahead of the next phase,” says Thaher Pelaseyed.
Professor Gunnar C. Hansson emphasizes the importance of translating research discoveries into concrete benefits.
“This shows the potential of basic research at Sahlgrenska Academy. The fact that discoveries made by the Mucin Biology Group can lead to new treatments for serious diseases also demonstrates the international relevance of our research,” he says.
MucoLife is now aiming to secure funding to enable it to begin phase I clinical trials in 2027.
